Turn $5,000 into $48,700 in Our
Next Stock of the Decade
If you missed out on the 974% gains our last Stock of the Decade, Monster Beverage, handed our Small Cap Confidential readers, you need to listen up.
Our next stock of the decade is set to meet—or even exceed—those incredible gains as our confirming research shows.
Once you see my complete profit profile on this medical devices juggernaut, you’ll quickly agree…
This Could Be an Easier Double Than The
974% Gains We Made In Monster Beverage
I’m Thomas Garrity, and that’s a big claim, I know—especially because it’s been our biggest winner to date and because we have not repeated those kinds of profits over the past few years.
But not when you see with your own eyes the number of profit triggers this company possesses for Monster Beverage-like growth, then you’ll understand why I added it to my Cabot Small-Cap Confidential holdings. And why I’m urging you to do the same thing before it rises another 300% or more in the months and years ahead.
Before I name it, I want to explain how I’ve been able to find this kind of profit-rich, game-changing small-cap stock with uncanny accuracy—in virtually all markets and at all times, for more than two decades.
How Innovation and Superior Stock Selection
Can Be Your Ticket to a Small Fortune Too
Here at Cabot Small-Cap Confidential, we have found that the secret to profitable investing is to invest in game-changing technologies that not only stand in the path of growth but revolutionize entire industries.
The reasons these companies have been so lucrative for us is they (1) change the way an entire industry does business and (2) have proprietary technologies that right from the beginning give them such a monopoly-like market share that few competitors can ever catch up.
- Priceline, for example, which changed the way the world traveled, handed investors 4,172% gains from January 2001 through 2010.
- Apple, which revolutionized the computer, music and phone industries, handed investors 3,900% returns during the same time.
- Netflix is another great example of a game-changing company that richly rewarded investors with 1,900% gains at the same time—all by changing the way Americans rent videos.
And as great as these small-cap juggernauts have been, our newest recommendation has the potential to hand us even greater returns.
How can this be?
Because our proprietary stock selection system has been designed not only to identify breakout sales, earnings, and profit margin expansion factors...
…but also to identify the specific disruptive, game-changing technologies that most analysts miss and that will ensure a company’s market share and technical superiority for years to come.
Simply put, the way my system generates buy signals can best be compared to the way an MRI scanner takes pictures inside your body.
But instead of giving you early warning of a potentially life-threatening disease, my system gives you an advance look at the companies and technologies that can make you rich, months and years before they take off.
This is precisely how we banked a 974% gain in Monster Beverage, a 558% gain in Silicom Ltd., a 508% gain in Bolt Technology, a 358% gain in HealthStream and a 403% gain in EzChip.
In other words, we identified these disruptive technologies in their early stages and held on for the ride.
This is also…
Why My Newest Recommendation Looks
a Lot Like Monster Beverage in the Early Days
Just like Monster Beverage’s breakthrough natural drink products revolutionized the beverage industry, this small-cap medical juggernaut is doing the same thing for the treatment of heart disease.
With heart disease the leading cause of death for both men and women, this is one medical stock on a growth trajectory that could easily surpass the big profits we made in Monster Beverage.
What makes me say so?
Because this company’s treatment for Peripheral Arterial Disease (PAD), which will affect one in 20 Americans in their lifetime, could make heart angioplasty obsolete.
Unlike angioplasty, which uses a metal mesh to inflate and stretch traumatized arteries to clear arterial blockages, this company’s treatment is like using a plumber’s snake to unclog your drain.
Just like a plumber’s snake, it also uses a spinning drill-bit to sand plaque from arterial walls. Without getting too technical, it does this in a way that significantly minimizes the rise of trauma and ischemia.
Since the company received FDA clearance to market this product, its stock price has risen an incredible 116% while its revenues have increased 24% quarterly.
Now that its arterial-cleaning solution has been proven for treating PAD, the company is in the final phases of having its arterial blocking products approved for treating Coronary Artery Disease (CAD), which is the most common form of heart disease and costs the United States more than $100 billion each year.
Those are just two factors that made this one pop on our radar screen. Take a quick look at these confirming dynamics and you’ll see why this could be my next Monster Beverage.
- Demand for this company’s heart-saving treatments will only grow larger as heart researchers have found that one in three of America’s 77 million baby boomers will develop heart problems.
- This small-cap company’s surgical technology solution offers less discomfort and quicker recovery than angioplasty—confirmed by a recent National Institute of Health study.
- With the company’s CAD treating-solution on the verge of getting FDA approval, the company continues to stand out as a takeover target. According to one top investment manager, "If they get that approval they'll get bought within six months."
- Which is why, if you can add this one to your holdings now in advance of final FDA approval, you could pile up your gains even faster than when Monster Beverage handed us 974% gains.
As I regularly remind my readers, it is extremely rare to find one company that not only has so many incredible profit triggers but also matches the profit profiles of our five biggest winners. That’s why I added this small-cap company to our holdings for 1,000%+ gains over the next five to ten years and highly recommend you follow suit. In fact, I so strongly believe that this new recommendation could ultimately become our next Monster Beverage, I want to give you the name of this company FREE along with a money-back trial subscription to Cabot Small-Cap Confidential.
1. To show you how profitable it can be to invest in small-cap, emerging technology companies right at the beginning of their biggest growth moves AND before they become front-page news, and
2. To introduce you to our limited-circulation Cabot Small-Cap Confidential investment advisory that targets and profits from these opportunities without you risking a dime. That way you can see for yourself if our long-term emerging stock investing approach is for you.
Why ONLY 24 Hours?
Because many of our Cabot Small-Cap Confidential recommendations tend to jump soon after we recommend them, as individual investors, hedge funds and institutional investors who know our 10-bagger track record and follow our recommendations begin to pile into our stocks.
However, by limiting our offer this way, we can help ensure you’ll grab the next wave of profits before the big money piles in and this stock breaks out again—and so you won’t miss a dime’s worth of profits.
BEST OF ALL
By joining us ahead of our 24-hour deadline, you’ll also lock in our best price for the next 90 days. With my lifetime CABOT money-back guarantee, there’s no way you can lose either.
When you do …
You’ll Also Find 15 More Game Changers
That Could Turn $5,000 into $48,700
Over the Next Ten Years
I speak, for example, of …
- The medical devices company whose breakthrough surgical devices could end back pain for millions of Americans.
- The biomedical blood safety company whose product protects millions around the world from HIV, hepatitis B, and hepatitis C as well as a broad range of life-threatening pathogens and viruses.
- The world's biggest beneficiary of rising food costs—a little known seed company that's making money hand over fist as farmers pull out all the stops to boost food production.
- The biotech company whose lifesaving inhalation therapies are improving the lives of thousands of people battling a myriad of lung diseases.
- The renewable energy company whose monopoly-like position in the geothermal sector has seen its revenues skyrocket 511% in the past 12 months.
- The molecular diagnostic company whose state-of-the-art testing services are not only enabling earlier detection of life-threatening disease but also resulting in thousands of saved lives.
These are just six of our 16 current game-changing recommendations that we’re targeting for 10-bagger profits over the next five to ten years.
Individually, each one controls a disruptive breakthrough technology that will turn its industry upside down no differently than Monster Beverage, Silicom Ltd., Bolt Technology, HealthStream, EzChip, Apple, Priceline and Netflix have in theirs.
Together, they will give you the opportunity to turn every $5,000 you invest now into $25,000, $35,000, $45,000 or more over the next five to ten years or your money will be promptly refunded—even that far down the road.
This Is Why We Limit Our Subscribers to Just 500—
and Require That Our Investors Not Share, Sell or Redistribute Our High-Profit Recommendations
A quick look at the 974%, 558%, 508%, 358% and 403% profits in Monster Beverage, Silicom Ltd., Bolt Technology, HealthStream and EzChip explains why.
Truth is, if we were to leave our membership open, then the whole world would know—at the same time—which companies we were investing in and you would not be able to buy them while their prices were cheap or before the hedge funds, pension funds and mutual funds jumped in.
That’s also why we require strict confidentiality from our members.
It is precisely this exclusivity and discretion that have helped my subscribers and readers enjoy so many life-changing gains from many of our incredible past recommendations.
This is how we plan to maintain this edge and keep your wealth growing—by keeping our circulation small and our recommendations private.
If this sounds like the kind of exclusive investing advisory, approach and profits that you’re looking for, you owe it to yourself to accept my incredible offer to get the name of my next Monster Beverage FREE… along with a 90-day, half-price subscription to Cabot Small-Cap Confidential.
With my lifetime “profit first” money-back guarantee, there’s no way you can lose either.
Here’s What Makes This Opportunity So Rare
Just like we limit our subscription to 500 readers, we must limit this introductory offer to the first 27 who say “Yes” today, because we have only 27 open memberships.
Once those spots are filled, this service will be closed until the next opening. And I can’t promise that will be anytime soon.
For these reasons, if you don’t take advantage of this opportunity to join us today, you may have to wait years to do so.
The reason is simple:
When you consistently deliver these kinds of double- and triple-digit profits year after year, investors stick with you over the long term. We think you will too, or you’ll receive a prompt refund of all unmailed issues—from day one and for the life of your subscription.
In fact, I specifically set it up this way so that you can see results over the long term before you give us your final decision.
That’s because—as you know—the path to 5,000%, 10,000% and 16,000% returns doesn’t happen overnight—but over time.
My complete, no-questions-asked, “profit first” money-back guarantee gives you the confidence to invest in our emerging growth plays over the long term, knowing that you can cancel for a full refund of all unmailed issues at any time because you are always protected by our 100% satisfaction guarantee—even when you renew—automatically extending my promise to you for as long as you’re a Small-Cap Confidential subscriber.
If you are already a Cabot subscriber, then you know that’s the same “profit first” approach we’ve honored for 43 years on our other advisories. You can count on it here too, when you join us at Small-Cap Confidential.
So if you’ve always wanted to try my Cabot Small-Cap Confidential investing advisory, today is the day.
By simply saying “Yes” to this 100% risk-free opportunity, you’ll get not only the chance to invest in our next 1,000%, 5,000% or 10,000% gainer without risking a dime…
…but also the opportunity to lock in my best price ever: just $175 for a 90-day subscription (reg. $350).
That comes to less than $2 a day—and a small investment to make to get in on the ground floor of Wall Street’s most profitable emerging growth companies.
Your introductory $2-a-day price includes:
- 24/7 access to our private website, featuring our archive of past recommendations and regular updates
- Weekly updates on our recommended companies
- Monthly research reports on our new game-changing recommendations
- My personal email so you can write me here at Cabot Small-Cap Confidential and ask me about my stock recommendations as well as my buy or sell signals
- My lifetime 100% satisfaction profit-first guarantee that covers you from day one through the very last day of your subscription
This is how Cabot Small-Cap Confidential has become one of the most respected and profitable investment advisories on Wall Street.
As our long-term track record clearly shows, you really can invest in and profit from game-changing companies and technologies when you spot them early and have the patience to hold on for the ride as we do.
Click Here Now to Get the Name of My Next 1,000% Gainer Sent Directly to Your Inbox Free
In the bargain, you’ll also get the full story on each one of our current 14 game-changing recommendations and a 90-day risk-free trial of our wealth-building advisory, along with my best price ever as part of a special introductory offer.
If our newest recommendations are just 1/100th as profitable as our biggest winners, you’ll grab 50% to 100% gains from each of them every six months or so and may never invest any other way again.
But you’ll need to hurry.
The last time we sent a similar offer to our Cabot family of readers, all our available slots were filled in less than 24 hours.
However, with only 27 spaces open this time, and at just $2 a day, my gut tells me that all our available spaces will be gone long before that.
So what are you waiting for?
- Check out the explosive profits our small-cap stocks can hand you.
- See how exciting it feels to turn $5,000 into $48,700 in the next five to ten years.
- Take FULL advantage of my lifetime 100% satisfaction guarantee to decide if Small-Cap Confidential is for you.
Mark my words: Once you grab your first 100% gain, I’ll bet I couldn’t pry your subscription from your hand if I tried.
I guarantee it will be one of the most profitable investing decisions of your investing life.
Editor, Cabot Small-Cap Confidential
P.S. I’ll never forget the day I sold Monster Beverage for a 974% gain and my readers saw a $5,000 investment soar to $48,700!
Or the day I sold Silicom Ltd. for a 558% gain; Bolt Technology for 508%; HealthStream for a 358% profit; EzChip for 403%; or any of our many double, triple and 10-bagger plays.
I know you’ll feel 10-feet tall and bulletproof too, when you get in on the ground floor of my next Monster Beverage TONIGHT and take profits with us here as well.
That’s why I’ve made it as easy as possible for our loyal Cabot readers to give Small-Cap Confidential a try.
That way you can see the difference our small-cap emerging growth stock advisory can make for your future—and without any risk or obligation to continue if you’re not 100% satisfied with your profits.
That’s why we expect our 27 open spaces to sell out long before tomorrow’s 24-hour deadline—especially with our first-time-ever $2-a-day price.
Trust your impulse and let your destiny unfold. Join us now here at Small-Cap Confidential today. You have nothing to lose and everything to gain.
This special offer ends today.